Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 13 , ISSUE 2 ( July-December, 2023 ) > List of Articles

Original Article

Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac

Freya Milagros Freyre, Jorge A Aguiar, Zurina Cinza, Nelvis Figueroa, Pablo Arsenio Diaz, Verena Lucila Muzio, Gilda Lemos, Giselle Freyre, Edelgis Coizeau, Chabeli Rodríguez, Eduardo Penton, Magalys Campos, Iván Luis Santos, Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Gerardo E Guillén, Julio Cesar Aguilar

Keywords : Chronic hepatitis B, HeberNasvac, Hepatitis B Virus, Hepatitis B surface antigen, Therapeutic vaccines

Citation Information : Freyre FM, Aguiar JA, Cinza Z, Figueroa N, Diaz PA, Muzio VL, Lemos G, Freyre G, Coizeau E, Rodríguez C, Penton E, Campos M, Santos IL, Al Mahtab M, Akbar SM, Guillén GE, Aguilar JC. Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac. Euroasian J Hepatogastroenterol 2023; 13 (2):73-78.

DOI: 10.5005/jp-journals-10018-1402

License: CC BY-NC 4.0

Published Online: 26-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

HeberNasvac is a recently developed therapeutic vaccine for chronic hepatitis B (CHB) administered by intranasal (IN) and subcutaneous (SC) routes in a 14 days/10 doses schedule. To compare different schedules and routes of immunizations, a group of patients received four different vaccination regimens in a placebo-controlled factorial study. Subsequently, patients were followed for a minimum time of 48 weeks. Samples collected at the end of the follow-up were compared with initial samples. Groups I and II received the product by IN/SC routes, every 14 and 7 days, respectively. Groups III and IV were treated by SC route alone following a 14 and 7 days schedule. A group of 21 CHB patients received the vaccine in four different schedules and eight patients received placebo for a total of 29 patients enrolled. The 61.9% of vaccinees reduced their VL ≥2Log compared with baseline levels and 25% in placebo group. The 47.6% of vaccines reduced HBV levels to undetectable, 25% in placebo. HBeAg loss and seroconversion to anti-HBeAg was only achieved in vaccinees, 4 out of 9 (44.4%), and 40% (8 out of 20) developed anti-HBs response, none in placebo group. Reduction of HBsAg level in ≥1Log was achieved in the 35.0% of vaccinees and in none of the placebo-treated patients. Considering the individual and factorial analysis, significant HBV DNA reduction was detected in groups I and II, immunized by IN/SC routes. A significantly higher proportion of patients reducing VL to ≥2Log was also detected grouping the patients treated by IN/SC routes (G I + II) and grouping those inoculated every 14 days (G I + III), with 72.7% and 63.6%, respectively, compared with the placebo group (25.0%). The patients immunized every 14 days (G I + G III) also reduced the HBsAg levels compared with baseline. In conclusion, after more than 48 weeks of treatment-free follow-up, HeberNasvac-treated patients demonstrated superior responses compared with the placebo group in terms of antiviral and serological responses. The factorial analysis evidenced that the schedule combining the IN route of immunization and the frequency of 14 days resulted in the stronger antiviral and serological responses. Present results support the study of IN-only immunization schedules in future and was consistent with previous results. Long-lasting follow-ups were done to explore histological variables and the progression of serological variables in order to detect late responders.


HTML PDF Share
  1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2): 507–539. DOI: 10.1002/hep.21513.
  2. Ott JJ, Stevens GA, Groeger J, Wirsma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212–2219. DOI: 10.1016/j.vaccine.2011.12.116.
  3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678–686. DOI: 10.1053/j.gastro.2005.11.016.
  4. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39(3):804–810. DOI: 10.1002/hep.20128.
  5. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51(6):1945–1953. DOI: 10.1002/hep.23568.
  6. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132(4): 1574–1585. DOI: 10.1053/j.gastro.2007.02.039.
  7. De Clercq E. The discovery of antiviral agents: Ten different compounds, ten different stories. Med Res Rev 2008;28(6):929–953. DOI: 10.1002/med.20128.
  8. Straley S and Terrault N. Overview of treatment of hepatitis B: Key approaches and clinical challenges. Curr Trat Options gastroenterol 2004;24 Suppl 1:23–29. DOI: 10.1055/s-2004-828675.
  9. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatol 2007;45(4):1056–1075. DOI: 10.1002/hep.21627.
  10. Cornberg M, Lok ASF, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report From the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2020;71(3):1070–1092.
  11. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1–98. DOI: 10.1007/s12072-015-9675-4.
  12. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009;3(5):561–569. DOI: 10.1586/egh.09.48.
  13. Michel ML, Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 2001;44(2–3):78–87. DOI: 10.1159/000050035.
  14. Thomas Fehr, Dace Skrstina, Paul Pumpens, et al. Zinkernagel. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA 1998;95(16):9477–9481. DOI: 10.1073/pnas.95.16.9477.
  15. Keeffe EB, Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5(3):285–294. DOI: 10.1016/j.cgh.2006.09.036.
  16. Aguilar JC, Lobaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004;82(5):539–546. DOI: 10.1111/j.0818-9641.2004.01278.x.
  17. Lobaina Y, Trujillo H, García D, et al. The effect of the parenteral route of administration on the immune response to simultaneous nasal – parenteral immunizations using a new HBV therapeutic vaccine candidate. Viral Immunology 2010;23(5):521–529. DOI: 10.1089/vim.2010.0024.
  18. Lobaina Y, García D, Blanco A, et al. The adoptive transfer of HBsAg-specific splenocytes from Balb/c congenic donors into HBsAg transgenic mice is not associated to histopathological damage. Euroasian J Hepato-Gastroenterol 2013;3(2):97–102. DOI: 10.5005/jp-journals-10018-1074.
  19. Betancourt AA, Delgado CA, Estevez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007;11(5): 394–401. DOI: 10.1016/j.ijid.2006.09.010.
  20. Fernández G, Sanchez AL, Jerez E, et al. Five-year follow-up of chronic Hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac. Euroasian J Hepatogastroenterol 2018;8(2):133–139. DOI: 10.5005/jp-journals-10018-1279.
  21. Akbar SM, Al-Mahtab M, Uddin MH, et al. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection. Hepatobiliary Pancreat. Dis. Int. 2013;12(4):363–369. DOI: 10.1016/s1499-3872(13)60057-0.
  22. Al-Mahtab M, Akbar SM, Aguilar JC, et al. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int 2013;7(4):981–989. DOI: 10.1007/s12072-013-9486-4.
  23. Akbar SM, Al-Mahtab M, Rahman S, et al. A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B. Hepatology 2013;58:4. DOI: 10.1002/hep26856.
  24. Al-Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS ONE 2018;13(8):e0201236. DOI: 10.1371/journal. pone.0201236.
  25. Yoshida O, Imai Y, Akbar SMF, et al. HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in a patients with chronic HBV infection: the results of 18 months follow-up. The Liver Meeting, AASLD, November 13–16, 2020.
  26. Al-Mahtab M, Akbar SM, Rahman S, et al. Safety, efficacy and immunogenecity of a therapeutic vaccine containing HBsAg and HBcAg by nasal route in patients with chronic hepatitis B. J Hepatol 2010;52:392.
  27. Lobaina Y, Garcia D, Abreu N, et al. Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun 2003;300(3):745–750. DOI: 10.1016/s0006-291x(02)02897-8.
  28. Byung O Lee, Amy Tucker, Lars Frelin, et al. Interaction of hepatitis B core antigen and the innate immune system. J Immunol 2009;182(11):6670–6681. DOI: 10.4049/jimmunol.0803683.
  29. Aguiar J, Rodríguez L, León Y, et al. Hepatitis B virus DNA quantification using a cost effective and simple real time PCR in Cuban carriers. J Infect Dis Ther 2014; (2): 49–58. DOI: 10.14205/2310-9386.2014.02.02.4.
  30. HeberNasvac: Recombinant therapeutic vaccine against the chronic Infection by the Hepatitis B Virus. Cuban Regulatory Agency (CECMED). Summary of product characteristics(2019).
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.